Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05227261Completed

Early Detection of Five Common Cancers Using the ctDNA Analysing Test

Role: collaborator

NCT03943940Phase 1Unknown

BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients

Role: lead

NCT03484741Phase 1Unknown

Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients

Role: lead

NCT02142842Phase 1Completed

Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis

Role: collaborator

NCT02645305Phase 1Unknown

Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease

Role: collaborator

All 5 trials loaded